Merck & Co., Inc. (MRK)
NYSE: MRK · Real-Time Price · USD
97.44
+0.90 (0.93%)
At close: Nov 20, 2024, 4:00 PM
97.40
-0.04 (-0.04%)
Pre-market: Nov 21, 2024, 5:35 AM EST
Merck & Co. Employees
Merck & Co. had 72,000 employees as of December 31, 2023. The number of employees increased by 3,000 or 4.35% compared to the previous year.
Employees
72,000
Change (1Y)
3,000
Growth (1Y)
4.35%
Revenue / Employee
$877,417
Profits / Employee
$168,722
Market Cap
246.49B
Employees Chart
Employees History
Date | Employees | Change | Growth |
---|---|---|---|
Dec 31, 2023 | 72,000 | 3,000 | 4.35% |
Dec 31, 2022 | 69,000 | 1,000 | 1.47% |
Dec 31, 2021 | 68,000 | -6,000 | -8.11% |
Dec 31, 2020 | 74,000 | 3,000 | 4.23% |
Dec 31, 2019 | 71,000 | 2,000 | 2.90% |
Dec 31, 2018 | 69,000 | 0 | - |
Dec 31, 2017 | 69,000 | 1,000 | 1.47% |
Dec 31, 2016 | 68,000 | 0 | - |
Dec 31, 2015 | 68,000 | -2,000 | -2.86% |
Dec 31, 2014 | 70,000 | -6,000 | -7.89% |
Dec 31, 2013 | 76,000 | -7,000 | -8.43% |
Dec 31, 2012 | 83,000 | -3,000 | -3.49% |
Dec 31, 2011 | 86,000 | -8,000 | -8.51% |
Dec 31, 2010 | 94,000 | -6,000 | -6.00% |
Dec 31, 2009 | 100,000 | - | - |
Sources: Annual number of employees according to filings submitted to the U.S. Securities and Exchange Commission (SEC). Data is also manually gathered from company press releases, IPO filings, and other official sources.
Related Stocks
Company Name | Employees |
---|---|
UnitedHealth Group | 440,000 |
Johnson & Johnson | 131,900 |
Thermo Fisher | 122,000 |
Abbott Laboratories | 114,000 |
AstraZeneca | 89,900 |
Novartis AG | 76,057 |
Novo Nordisk | 64,319 |
AbbVie | 50,000 |
MRK News
- 1 hour ago - Merck Data at the ASH 2024 Annual Meeting Highlights Promising Hematology Pipeline With Diverse Range of Investigational Assets and Novel Modalities - Business Wire
- 1 day ago - Merck Announces First-Quarter 2025 Dividend - Business Wire
- 1 day ago - Merck: Seriously Undervalued At Peak Pessimism (Rating Upgrade) - Seeking Alpha
- 1 day ago - Merck's Cancer Shot Works. Its Post-Keytruda Plans Are Shaping Up Again. - Barrons
- 1 day ago - Merck says blockbuster cancer drug met main goals in trial of new under-the-skin formulation - Market Watch
- 2 days ago - Merck says Keytruda injection on par with approved IV version in trial - Reuters
- 2 days ago - Merck Announces Phase 3 Trial of Subcutaneous Pembrolizumab With Berahyaluronidase Alfa Met Primary Endpoints - Business Wire
- 3 days ago - Merck Among 10 Companies To Announce Annual Dividend Increases In Second Half Of November - Seeking Alpha